本文選題：非小細(xì)胞肺癌 + 甲磺酸阿帕替尼��； 參考：《中華腫瘤防治雜志》2017年07期

【摘要】：目的甲磺酸阿帕替尼是一種新型的針對(duì)血管內(nèi)皮生長(zhǎng)因子受體2的酪氨酸抑制劑,已被證實(shí)是治療晚期胃癌的有效靶向藥物。本研究旨在觀察甲磺酸阿帕替尼治療三線及三線以上晚期非小細(xì)胞肺癌的臨床療效及不良反應(yīng)。方法分析安陽(yáng)市腫瘤醫(yī)院2015-02-10-2016-06-10晚期非小細(xì)胞肺癌40例的臨床資料,所有患者均經(jīng)組織病理或細(xì)胞學(xué)確診。三線及三線以上口服甲磺酸阿帕替尼500mg/d,4周后開(kāi)始療效評(píng)價(jià)。結(jié)果 40例患者均可評(píng)價(jià)療效,完全緩解(complete response,CR)0例,部分緩解(partial response,PR)9例,疾病穩(wěn)定(stable disease,SD)19例,疾病進(jìn)展(progressive disease,PD)12例,客觀緩解率(overall response rate,ORR)為22.5%(9/40),疾病控制率(disease control rate,DCR)為70.0%(28/40)。Ki-67表達(dá)水平與ORR相關(guān),χ~2=11.335,P=0.003;同時(shí)Ki-67表達(dá)水平與DCR相關(guān),χ~2=6.427,P=0.04。單因素分析顯示,PS評(píng)分0~1與PS評(píng)分≥2比較中位無(wú)進(jìn)展生存期(progression-free survival,PFS)差異有統(tǒng)計(jì)學(xué)意義,P=0.022。療效評(píng)價(jià)PR、SD、PD 3組間比較中位PFS差異有統(tǒng)計(jì)學(xué)意義,P=0.017。多變量回歸分析顯示,PS評(píng)分0~1、療效評(píng)價(jià)PR可以作為PFS延長(zhǎng)的獨(dú)立預(yù)測(cè)指標(biāo),P0.05。常見(jiàn)不良反應(yīng)為輕度高血壓、蛋白尿和口腔黏膜炎。結(jié)論甲磺酸阿帕替尼三線及三線以上治療晚期非小細(xì)胞肺癌安全有效,不良反應(yīng)輕。
[Abstract]:Objective Apatinib mesylate is a novel tyrosine inhibitor targeting vascular endothelial growth factor receptor 2 and has been proved to be an effective target drug in the treatment of advanced gastric cancer.The purpose of this study was to observe the clinical efficacy and adverse reactions of Apatinib mesylate in the treatment of advanced non-small cell lung cancer (NSCLC).Methods the clinical data of 40 patients with advanced non-small cell lung cancer (NSCLC) in Anyang Cancer Hospital were analyzed. All patients were confirmed by histopathology or cytology.The efficacy was evaluated 4 weeks after oral administration of Apatinib Mesilate 500 mg / d.Results all the 40 patients could evaluate the curative effect. There were 0 cases of complete remission, 9 cases of partial response to PRN, 19 cases of stable disease, 12 cases of progressive disease, 12 cases of progressive disease, 9 cases of partial response, 19 cases of stable disease and 12 cases of progressive disease.Univariate analysis showed that there was a significant difference in the median progression-free survival PFSs between PS score 0 and PS score 鈮，

本文編號(hào)：1735862